US EditionAC-201 Shows Strong Phase 2 Results in Psoriasis Trial
- Accropeutics announced positive results on May 20, 2025, from a multicenter, randomized, double-blind Phase 2 trial of AC-201 in 145 Chinese patients with moderate-to-severe plaque psoriasis.
- The study evaluated the efficacy and safety of a novel small-molecule TYK2/JAK1 inhibitor administered orally in patients with moderate-to-severe plaque psoriasis, using measures such as PASI-75 and sPGA scores at 12 weeks compared to placebo.
- All three dosing groups met the primary and key secondary endpoints with PASI-75 response rates well above placebo , including a 20% PASI-90 at 25mg BID and 71.4% sPGA-0/1 at 50mg BID doses.
- AC-201 showed no serious adverse events or discontinuations, was generally well tolerated, with most adverse events mild or moderate and common events including upper respiratory infections and hypertriglyceridemia.
- The demonstrated efficacy and safety of AC-201 support Accropeutics' intention to move forward with Phase 3 trials targeting psoriasis and other immune-related conditions, as highlighted by CEO Dr. Xiaohu Zhang.
Insights by Ground AI
Does this summary seem wrong?
51 Articles
51 Articles
All
Left
3
Center
15
Right
5
Bennington Banner+49 Reposted by 49 other sources
Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis
Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing groups at Week 12AC-201 was generally well tolerated at all dose levels with no SAEs or AEs leading to discontinuationEfficacy and safety findings…
Coverage Details
Total News Sources51
Leaning Left3Leaning Right5Center15Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
13%
C 65%
R 22%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage